Immunotherapy of hepatocellular carcinoma

PMID: 20528121
Journal: Expert review of gastroenterology & hepatology (volume: 4, issue: 3, Expert Rev Gastroenterol Hepatol 2010 Jun;4(3):345-53)
Published: 2010-06-01

Korangy F, Höchst B, Manns MP, Greten TF


Hepatocellular carcinoma (HCC) represents the third most common cause of cancer-related death worldwide and efficient treatment options are urgently needed. Based on its pathogenesis, in addition to a number of correlative studies, immunotherapy represents a potential therapeutic option for patients with HCC. However, tumors have also evolved numerous immune escape mechanisms, including the generation of cells with immune suppressor functions, such as Tregs and myeloid-derived suppressor cells. It has been shown that these suppressor cells mask tumor-specific immune responses in patients with HCC. Different immunotherapeutic approaches including peptide- and dendritic cell-based therapies have demonstrated promising results in patients with HCC. However, we propose that any of these immunotherapeutic approaches needs to be combined with a therapy specifically targeting suppressor cells in HCC.